Equities

Tibet Rhodiola Pharmaceutical Holding Co

600211:SHH

Tibet Rhodiola Pharmaceutical Holding Co

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)36.30
  • Today's Change-1.72 / -4.52%
  • Shares traded6.67m
  • 1 Year change-10.68%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

TIBET RHODIOLA PHARMACEUTICAL HOLDING CO. is a China-based company principally engaged in the production and distribution of pharmaceuticals. The Company operates its businesses through the distribution of proprietary drug products, as well as the processing of pharmaceuticals and others. The Company conducts its businesses primarily in South China, North China, East China, Central China and overseas markets.

  • Revenue in CNY (TTM)2.94bn
  • Net income in CNY737.44m
  • Incorporated1999
  • Employees601.00
  • Location
    Tibet Rhodiola Pharmaceutical Holding CoNo. 19, Beijing Middle RoadLASA 850000ChinaCHN
  • Phone+86 2 886653915
  • Fax+86 2 886660740
  • Websitehttp://www.xzyy.cn
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jiangsu Sinopep Allsin Bphrmctcl Co Ltd1.58bn421.47m12.04bn1.55k29.074.60--7.641.881.887.1411.910.42861.193.671,020,281.0011.585.8616.997.5967.1255.4127.0117.200.91224.020.347727.5958.6932.2426.2029.9927.32--
Guobang Pharma Ltd5.71bn702.28m12.13bn4.23k17.221.55--2.121.261.2610.2614.030.55993.297.841,350,536.006.8710.368.8814.2423.8727.4912.2715.011.70--0.199218.24-6.4910.28-33.4923.7735.60--
Henan Lingrui Pharmaceutical Co., Ltd.3.56bn675.80m12.23bn2.53k17.964.23--3.431.201.206.345.100.74892.2410.181,408,620.0014.2010.6823.5216.5672.3574.4218.9614.920.9579--0.007372.8010.3110.0322.0918.49-16.4739.77
Tibet Rhodiola Pharmaceutical Holding Co2.94bn737.44m12.25bn601.0014.743.38--4.172.582.589.6911.260.62641.546.794,894,779.0015.8012.4420.8315.7193.3690.5125.2220.433.447.740.126450.4122.6924.98116.5630.01-1.4848.97
Zhejiang CONBA Pharmaceutical Co., Ltd.6.46bn486.79m12.26bn8.41k24.951.84--1.900.19120.19122.542.590.6182.394.56768,224.604.986.776.9310.5051.4763.248.0611.101.24--0.078142.3212.20-0.826765.20-6.21-11.645.92
Data as of Nov 22 2024. Currency figures normalised to Tibet Rhodiola Pharmaceutical Holding Co's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

2.57%Per cent of shares held by top holders
HolderShares% Held
Essence Fund Co., Ltd.as of 30 Jun 20242.37m0.74%
HuaAn Fund Management Co., Ltd.as of 30 Jun 20241.13m0.35%
China Asset Management Co., Ltd.as of 30 Jun 2024957.79k0.30%
The Vanguard Group, Inc.as of 06 Nov 2024918.63k0.29%
China Southern Asset Management Co., Ltd.as of 30 Jun 2024745.19k0.23%
China Universal Asset Management Co., Ltd.as of 30 Jun 2024498.69k0.16%
Gfund Management Co., Ltd.as of 30 Jun 2024481.69k0.15%
GF Fund Management Co., Ltd.as of 30 Jun 2024457.96k0.14%
Penghua Fund Management Co., Ltd.as of 30 Jun 2024396.89k0.12%
HFT Investment Management Co., Ltd.as of 30 Jun 2024329.80k0.10%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.